NCT05475925: A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 200 planned
- Started
- 13 Jul 2022
- Primary completion
- Dec 2026
- Arms
- Part A Dose Escalation 1 mg/kg of DR-01, Part A Dose Escalation 3 mg/kg of DR-01, Part A Dose Escalation 6 mg/kg of DR-01, Part A Dose Escalation 10 mg/kg of DR-01, Part A Dose De-escalation 0.3 to <1 mg/kg of DR-01, Part B Dose Expansion (Cohort B1) Optimized Dose/Regimen of DR-01, Part B Dose Expansion (Cohort B2) Optimized Dose/Regimen of DR-01
- Results
- None posted
- 13 Jul 2022: Trial started
- 27 Jul 2022: Trial registered